Persistence with teriparatide in patients with osteoporosis: the UK experience

被引：0
|
作者：
N. K. Arden
S. Earl
D. J. Fisher
C. Cooper
S. Carruthers
M. Goater
机构：
[1] Southampton General Hospital,MRC Epidemiology Resource Centre, University of Southampton
[2] Southampton General Hospital,Department of Rheumatology
[3] Healthcare at Home,undefined
[4] Eli Lilly and Company,undefined
来源：
Osteoporosis International | 2006年 / 17卷
关键词：
Adverse events; Compliance; Osteoporosis; Persistence; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1626 / 1629
页数：3
相关论文
共 50 条
  • [21] Indications to teriparatide treatment in patients with osteoporosis
    Rizzoli, Rene
    Kraenzlin, Marius
    Krieg, Marc-Antoine
    Mellinghoff, Hans-Ulrich
    Lamy, Olivier
    Lippuner, Kurt
    SWISS MEDICAL WEEKLY, 2011, 141
  • [22] Efficacy of raloxifene and teriparatide in patients with osteoporosis
    Marie Lofthouse
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (4): : 182 - 183
  • [23] Clinical experience with teriparatide (TPDT) in the treatment of severe osteoporosis
    Finkenstedt, G.
    Finkenstedt, A.
    Gasser, R. W.
    Götsch, C.
    BONE, 2006, 39 (05) : S39 - S40
  • [24] 10 YEARS EXPERIENCE OF USING TERIPARATIDE IN SEVERE OSTEOPOROSIS
    Siddiqi, M.
    Murray, A.
    Gatignol, A.
    Ohare, J.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S220 - S220
  • [25] Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
    Ryo Fujita
    Tsutomu Endo
    Masahiko Takahata
    Kentaro Haraya
    Hisataka Suzuki
    Itaru Oda
    Masahiro Kanayama
    Tsuyoshi Asano
    Keiichi Shigenobu
    Akira Iwata
    Katsuhisa Yamada
    Hirohito Takeuchi
    Hisanori Ohura
    Daisuke Yoneoka
    Norimasa Iwasaki
    Journal of Bone and Mineral Metabolism, 2022, 40 : 782 - 789
  • [26] CLINICAL EXPERIENCE OF 1-34PTH (TERIPARATIDE) ON SEVERE OSTEOPOROSIS PATIENTS IN TAIWAN
    Yu, C.
    Lee, P. K.
    Chen, C.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 384 - 385
  • [27] Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
    Fujita, Ryo
    Endo, Tsutomu
    Takahata, Masahiko
    Haraya, Kentaro
    Suzuki, Hisataka
    Oda, Itaru
    Kanayama, Masahiro
    Asano, Tsuyoshi
    Shigenobu, Keiichi
    Iwata, Akira
    Yamada, Katsuhisa
    Takeuchi, Hirohito
    Ohura, Hisanori
    Yoneoka, Daisuke
    Iwasaki, Norimasa
    JOURNAL OF BONE AND MINERAL METABOLISM, 2022, 40 (05) : 782 - 789
  • [28] ADHERENCE IN PATIENTS WITH SEVERE OSTEOPOROSIS TREATED WITH TERIPARATIDE
    Ziller, V.
    Zimmermann, S-P.
    Ziller, M.
    Hadji, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 34 - 34
  • [29] Treatment of osteoporosis with Teriparatide in anorexia nervosa patients
    Toshie, Sasaki
    Takao, Kodama
    Chiemi, Nakamoto
    Yutaka, Suzuki
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2019, 88 : 130 - 130
  • [30] TREATMENT OF OSTEOPOROSIS WITH TERIPARATIDE IN ANOREXIA NERVOSA PATIENTS
    Sasaki, T.
    Kodama, T.
    Nakamoto, C.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S463 - S463
12345